Picture Kentro Design Corporate and Web Design Berlin 650x65px
Organisation › Details

Cherry Biolabs GmbH

Cherry Biolabs is a spin-off from the University Hospital Würzburg. The company holds the exclusive license for the Hemibody platform technology granted by the University Würzburg. Cherry Biolabs' lead program is a Hemibody pair designed to eliminate Multiple Myeloma. The company seeks to build an internal drug pipeline and to license out the technology on a target-specific basis. The program to develop the Hemibody technology was funded by the "Bavarian m4 Award", the "GO-Bio Gründungsoffensive Biotechnologie" from the German Federal Ministry of Education and Research, the Comprehensive Cancer Center Mainfranken (CCC) in Würzburg and the society "Hilfe im Kampf gegen Krebs e.V." *


Period Start 2019-01-01 established (s-off
  Predecessor University Hospital Würzburg (Universitätsklinikum Würzburg)
Products Industry BIOTECH
  Industry 2 Hemibody technology
Person Person Stuhler, Gernot (Cherry Biolabs 202011 CEO + Founder + Prof at Univ Hospital Würzburg)
Region Region Würzburg
  Country Germany
  Street 15 Friedrich-Bergius-Ring
  City 97076 Würzburg
  Tel +49-931-201-444-23
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: MorphoSys AG. (11/11/20). "Press Release: MorphoSys and Cherry Biolabs Announce Licensing of Hemibody Technology". Planegg & Würzburg.
Record changed: 2020-11-11


Picture [iito] Plain Stupid Simple 650x80px

More documents for Cherry Biolabs GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top